Though a start-up, the assembled team of Luminary Therapeutics includes cellular therapy veterans, industry leaders, and well-established and respected cancer geneticist leaders from the biotech space and related consulting entities. The assembled team describes Luminary Therapeutics as a pre-clinical cell therapy company developing next generation non-viral autologous cell treatments for cancers as well as autoimmune diseases. Luminary is bringing to market cellular therapies aimed at overcoming antigen escape - applicable to solid tumors as well as to key autoimmune diseases. The firm's primary focus is to develop CAR T and other next generation cell therapies that address the antigen escape issue present with existing therapies. To that end - to reduce safety concerns, costs, and time delays associated with viral based cell therapies - Luminary is utilizing Bio-Techne's TcBuster⢠transposon technology: a firm with which Luminary's manageent have previous association. Luminary seeks novel next generation licensing opportunities with strong intellectual property (IP) for the treatment of solid tumors and in underserved disorders
